8-K
filed May 21, 2026, 4:58 PM ET
ticker BVS
CIK 0001665988
regulatory
confidence high
sentiment neutral
materiality 0.30
Bioventus Exogen device reclassified by FDA, CMS updates reimbursement rates; company reiterates 2026 guidance
Bioventus Inc.
- FDA reclassified non-invasive bone growth stimulators, including Bioventus' Exogen Ultrasound Bone Healing System, from Class III to Class II on April 16, 2026.
- CMS updated Medicare fee schedule for HCPCS codes E0747, E0748, and E0760 for services on or after May 18, 2026.
- Bioventus does not expect material impact from reimbursement rate changes on its FY2026 financial results.
- Company reiterates previously issued 2026 financial guidance despite the regulatory changes.
- Bioventus continues to evaluate long-term impact; future CMS actions could require revised outlook.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001665988-26-000029
- form_type
- 8-K
- ticker
- BVS
- cik
- 0001665988
- company_name
- Bioventus Inc.
- filed_at
- 2026-05-21T20:58:18+00:00
- discovered_at
- 2026-05-21T20:59:00.279763+00:00
- generated_at
- 2026-05-21T21:01:18.775768+00:00
- sec_items
- ["7.01"]
- event_type
- regulatory
- sentiment
- neutral
- materiality_score
- 0.3
- calibrated_materiality_score
- 0.3
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001665988-26-000029
- json_url
- https://secwatch.observer/filing/0001665988-26-000029.json
- markdown_url
- https://secwatch.observer/filing/0001665988-26-000029.md
- text_url
- https://secwatch.observer/filing/0001665988-26-000029.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1665988/000166598826000029/0001665988-26-000029-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1665988/000166598826000029/bvs-20260521.htm
- generated_by_model
- deepseek-v4-flash:cloud
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
XCUR
Exicure gets Nasdaq delinquency notice for late 10-Q; files next day, says compliance regained
EXICURE, INC.
June 1, 2026, 3:30 PM ET
regulatory
Items 7.01, 9.01
same SEC item: 7.01
same event type: regulatory
similar materiality
Filing page
SEC filing
MSS
Maison Solutions regains Nasdaq minimum bid price compliance; listing continues
Maison Solutions Inc.
May 12, 2026, 1:22 PM ET
regulatory
Items 7.01, 8.01, 9.01
same SEC item: 7.01
same event type: regulatory
similar materiality
Filing page
SEC filing
GENC
Gencor receives NYSE American delinquency notice for late Q2 2026 10-Q filing
GENCOR INDUSTRIES INC
June 1, 2026, 4:09 PM ET
regulatory
Items 3.01, 7.01, 9.01
same SEC item: 7.01
same event type: regulatory
Filing page
SEC filing
NJR
NJNG files base rate case seeking $157.6M increase; offers 8.9% winter bill cut
NEW JERSEY RESOURCES CORP
June 1, 2026, 4:03 PM ET
regulatory
Items 7.01, 9.01
same SEC item: 7.01
same event type: regulatory
Filing page
SEC filing
ELTP
Elite Pharmaceuticals files ANDA for generic anticoagulant; $26B brand market, no generic available
ELITE PHARMACEUTICALS INC /NV/
June 1, 2026, 7:00 AM ET
regulatory
Items 7.01, 9.01
same SEC item: 7.01
same event type: regulatory
Filing page
SEC filing
ATNM
Actinium receives NYSE American non-compliance notice for low stockholders' equity; must submit plan by June 26
Actinium Pharmaceuticals, Inc.
May 29, 2026, 5:10 PM ET
regulatory
Items 3.01, 7.01, 9.01
same SEC item: 7.01
same event type: regulatory
Filing page
SEC filing
REPL
Replimune to resubmit RP1 BLA for advanced melanoma; FDA agrees to prioritize review
Replimune Group, Inc.
May 29, 2026, 9:56 AM ET
regulatory
Items 7.01, 9.01
same SEC item: 7.01
same event type: regulatory
Filing page
SEC filing
BDX
BD resumes ChloraPrep shipments after voluntary hold; all final release testing acceptable
BECTON DICKINSON & CO
May 29, 2026, 8:39 AM ET
regulatory
Items 7.01, 9.01
same SEC item: 7.01
same event type: regulatory
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.